Watch Gabather’s CEO Michael-Robin Witt present the company and the way ahead in BioStock’s studio in Lund.
Läs merKategori: Uncategorized
Biostock: Gabather’s aims to impact the neurodegeneration field
Neurodegeneration is a global societal crisis, affecting an increased number of people each year. Despite decades of research, effective therapeutic treatments for diseases like Alzheimer’s and Parkinson’s are still lacking, forcing biotech and pharma companies to pursue an out-of-the-box approach. One of these is Gabather, a Swedish biotech developing drugs
Läs merBiostock: Gabather approaching initial target engagement study results
Gabather’s target engagement study with the lead candidate GT-002, a treatment for neuropsychiatric disorders, is expected to produce its first results by the end of the year. This according to the company’s CEO, Michael-Robin Witt, who joined BioStock for an interview. Läs mer
Läs merBiostock: Gabather’s lead candidate moves forward in the clinic
Swedish biotech Gabather has received the approval from the Portuguese authorities to go ahead with a target engagement study to complete the phase I evaluation of GT-002, the company’s candidate targeting mood disorders. As patient recruitment for the study proceeds, BioStock got in touch with CEO Michael-Robin Witt to learn
Läs merDagens Industri: Forskningskamp i skuggan
Läs mer hos Dagens Industri
Läs merAktieportföljen Live 2021-11-27
Hör Michael Robin Witt (CEO) presentera Gabather hos Aktieportföljen Live den 24e november 2021.
Läs merBiostock: Gabather poised to complete phase I with GT-002
Aktiespararna: Aktiedagen Stockholm
VD Michael-Robin Witt presenterar Gabather på Aktiespararnas Aktiedagen i Stockholm 7 september 2021
Läs merCEO ANFÖRANDE PÅ ÅRSSTÄMMAN 2021
BioStock Life Science Spring Summit 2021
CEO Michael-Robin Witt presents Gabather at the spring edition of BioStock Life Science Summit 2021.
Läs mer